Enhancing product value
to improve asset sales
As the global pharmaceutical market evolves, the traditional routes that new products followed to achieve commercialization have also changed. Many major biopharmaceutical companies are now acquiring early-stage products, adding value by moving them through the development process, then selling the products as proven therapies that are ready for the marketplace – a strategy that allows companies to leverage their development resources and product expertise while avoiding the risks and pitfalls of taking a product to market.
Of course, there is also risk involved in acquiring the right products, selecting the best indications, designing trials to generate the strongest clinical data, and finding an appropriate buyer to maximize the sale value of the developed products. PAREXEL helps you minimize that risk with our full range of proven clinical services, therapeutic area knowledge, global reach, and in-depth regulatory and market experience.
Our expertise in Phase I/IIa and Proof-of-Concept studies is particularly valuable for this approach to product development, enabling our partners to make better-informed product acquisition decisions that decrease the risk of failure in the later stages of development. Equally important, our long experience in every phase of product development gives us the resources to help you reduce costs and shorten development times to maximize product value.
PAREXEL’s comprehensive array of services for the development and sale of new biopharmaceutical products includes:
- Due diligence and gap analysis of early-stage products
- Clinical development planning and cost analysis
- Regulatory strategies
- Product positioning services
- Market analysis
- Pricing and reimbursement strategies
- Complete clinical research services, Phase I-IV